Truist Financial Maintains Hold Rating on Editas Medicine with $3.71 Average Price Target

Truist Financial analyst Joon Lee maintains a Hold rating on Editas Medicine with a $3.71 average price target, representing a 20.45% upside from current levels. Lee has a 5-star rating and a 50.36% success rate. The analyst consensus on Editas Medicine is a Moderate Buy, with a current market cap of $191.7M and a P/E ratio of -1.08.

Editas Medicine (NASDAQ:EDIT) has seen a surge in analyst optimism, with several firms upgrading their price targets and ratings on the gene-editing company. H.C. Wainwright recently raised its price target to $5.00 from $3.00, citing progress in the company's pipeline and a more favorable expense trajectory [1]. Similarly, Robert W. Baird increased its target to $6.00 from $4.00, maintaining an "outperform" rating [2]. These upgrades come as Editas shares have surged over 114% in the past six months, with analyst targets ranging from $1 to $6 per share [1].

The upgrades follow Editas' announcement that it expects to select its first in vivo lead candidate in September 2025, targeting either hematopoietic stem cells for sickle cell disease and/or beta thalassemia, or hepatocytes for an undisclosed indication [1]. The company plans to submit an Investigational New Drug application by mid-2026, with first-in-human dosing expected in the second half of 2026. Management has reiterated plans to nominate and disclose an additional cell/tissue target by the end of 2025, with in vivo proof-of-concept targeted for 2027 [1].

Truist Financial analyst Joon Lee maintains a Hold rating on Editas Medicine with a $3.71 average price target, representing a 20.45% upside from current levels [3]. The analyst consensus on Editas Medicine is a Moderate Buy, with a current market cap of $191.7M and a P/E ratio of -1.08 [3]. Despite the positive analyst sentiment, Editas reported a quarterly loss of $0.63 per share in its second-quarter 2025 earnings, missing analysts' expectations [2].

Institutional investors have also shown interest in Editas Medicine, with several hedge funds increasing their stakes in the company. JPMorgan Chase & Co., Invesco Ltd., Renaissance Technologies LLC, Raymond James Financial Inc., and XTX Topco Ltd. have all increased their positions in Editas Medicine over the past quarter [2].

Editas Medicine, a clinical-stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology, with EDIT-101 in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis and reni-cel for sickle cell disease and transfusion-dependent beta-thalassemia [2].

References:
[1] https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-editas-medicine-stock-price-target-to-5-on-pipeline-progress-93CH-4195173
[2] https://www.marketbeat.com/instant-alerts/editas-medicine-nasdaqedit-price-target-raised-to-600-2025-08-13/
[3] https://www.stocktitan.net/news/EDIT/